1

Forward-Looking Statements
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These
statements relate to future events or the Companys future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the
Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In
some cases, forward-looking statements can be identified by terminology such as may, will, could, would,
should, expect, plan, anticipate, intend, believe, estimate, predict, potential or other comparable
terminology. All statements other than statements of historical fact could be deemed forward-looking, including any
expectations regarding investment returns; any projections of financial information; any statements about historical
results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management
for future operations; any statements of expectation or belief regarding future events, potential markets or market size,
or technology developments; and any statements of assumptions underlying any of the items mentioned. The Company
has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While
the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking
statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the
Companys control. These and other important factors may cause actual results, performance or achievements to differ
materially from those expressed or implied by these forward-looking statements. These statements may involve risks
and uncertainties that could cause actual results to differ materially from the expected results. Such risks include but
are not limited to the risk factors set forth in the Companys most recent Form 10-K, Form 10-Q and other filings with the
Securities and Exchange Commission (SEC). Investors are urged to review the Companys SEC filings. The forwardlooking statements in this presentation are made only as of the date hereof. Except as required by law, the Company
assumes no obligation and does not intend to update these forward-looking statements or to conform these statements
to actual results or to changes in the Company's expectations.

NASDAQ: IVTY

Philip Sawyer, Chief Executive Officer

Jim Mackaness, Chief Financial Officer

of all surgical procedures are open

minimally invasive and minimal access*
5

* Based on company estimate for the U.S.

Company Snapshot*
Proprietary Intelligent Photonics Technology

Platform Technology--9 Product Families

~162,000 Procedures
~80% of Revenue from SingleUse Devices
~$2.0B US Market
>61% YoY Revenue Growth 2015 vs. 2014
7

*As of March 31, 2016

overhead
lights

headlights

fiber
optics

POOR
VISUALIZATION

10

10

01.
SOLID CORE
OPTICAL POLYMER
02.
TOTAL INTERNAL
REFLECTION AND LIGHT
MIXING

03.
REFRACTIVE
MICROSTRUCTURES

Intelligent

Photonics
Technology

04.
THERMALLY COOL
ILLUMINATION

11

11

01. SOLID CORE

OPTICAL POLYMER

01.
SOLID CORE
OPTICAL POLYMER

Efficient coupling

Less heat
buildup
Efficient transmission of
light

12

12

02. TOTAL INTERNAL

REFLECTION
AND LIGHT MIXING
Light mixing reduces
glare and bright spots

02.
TOTAL INTERNAL
REFLECTION AND LIGHT
MIXING

Efficient transmission of
light prior to extraction

13

13

03. REFRACTIVE
MICROSTRUCTURES
Broad, uniform,
volumetric
illumination

03.
REFRACTIVE
MICROSTRUCTURES
Off-axis light
extraction
Reduced
shadows and
glare

14

14

TEMPERATURE (C) *

50.3C
maximum

At 44C and above, a

burn can occur

33.2C
maximum

Traditional
Fiber Optic
15

* Per co. bench testing

Intelligent
Photonics
Technology

LIGHT PROJECTION *

Traditional
Fiber Optic
16

* Per co. bench testing

Intelligent
Photonics
Technology

XT
System

Eika

17

Eivector

Saber
Yankauer

Breiten

Drop-in

Handheld

Saber
Frazier

Eipex

Retractor

Eikon

Eiberg

17
17

18

19

Initial US Beachhead Specialties TAM $1.1B

*Company estimate
20

$2B US Total Available Market

Specialties
CERVICAL (Spine)

SHOULDER
(Ortho)
BREAST
RECONSTRUCTION

BREAST
ONCOLOGY
LUMBAR
(Spine)
HIP (Ortho)

Other Specialties

21

TRAUMA/TUMOR
(Ortho)

Breast Oncology and Reconstruction Opportunity

Key Procedure Targets

22

Nipple Sparing Mastectomy

Skin Sparing Mastectomy
Breast Reconstruction
Lumpectomy

Superior Visualization During...

Nipple Sparing Mastectomy

23

Breast Surgeon Survey Results*

100

92

92

92

report Eikon improves surgical efficiency

in performing NSMs

report Eikon improves patient safety

24

report that Eikon reduces procedure

time for NSMs. Approximately 36 minutes
OR time saved

* Survey of 12 breast oncology surgeon thought leaders

report Eikon reduces heat and thermal

hazards in operating room

RETROSPECTIVE CHART REVIEW OF NIPPLE SPARING MASTECTOMIES WITH AND WITHOUT AN

ENABLING INTRACAVITY ILLUMINATION AND VISUALIZATION SYSTEM

Authors: Beth Baughman DuPree MD, FACS, ABIHM, William Scarlett DO, FACS, FACOS, FAACS,
Anna Smaron, Marie Cassese, Darren Eskow, and Jeff Gross

Affiliations: Adjunct Assistant Professor of Surgery University of Pennsylvania, Philadelphia PA,

Chairman Department of Surgery Holy Redeemer Hospital, Medical Director Integrative Medicine
Holy Redeemer Health System, Meadowbrook, PA Associate Professor of Plastics Surgery,
PCOM, Philadelphia PA, Medical Director of Bucks County Aesthetic Center, Bensalem, PA

Procedure: Unilateral and Bilateral Nipple Sparing Mastectomy

Results:*
Average of 31 min. reduction in anesthesia time in bilateral NSM
20% increase in procedures among patients with C and D cup size
100% decrease in compromised flaps in combined unilateral/bilateral surgeries**
70% decrease in epidermolysis in combined unilateral/bilateral surgeries**
_____________________________________________________________________________

Total potential savings of $580 to $2000 per procedure using Invuity devices***
* Results reflect changes after surgeon adoption of Invuitys Eikon illuminated retractor system
** Due to introduction of Invuity's Eikon Illuminated retractor system and potentially the advanced electrosurgical device
*** Study and economic analysis performed by leading outside healthcare consulting firm

25

25
25

 Surgeon Certification and Training Program on

Oncoplastic Techniques
Womens Health FocusBreast, Thyroid,
Gynecology
Center of Excellence Certification and Designation

Online
Hidden Scar Centers of
Excellence Finder at
BreastCancerSurgery.com
Hidden Scar Certified Surgeon
Finder at
BreastCancerSurgery.com
My Hidden Scar Microsite at
MyHiddenScar.com
Social media (Facebook, Twitter,
Pinterest)

26

External Marketing

Radio Spots
Print Ads
Billboard Ads
Media Relations/PR
Newsletter Templates
Website templates
Patient Education Presentation
Referral Letters

Internal Marketing
On-hold message
Waiting Room Patient Education
Video
Lobby/Waiting Room Displays and
Wall Posters
Patient Education Brochures

26
26

27

27
27

Eivector

Eipex

Orthopedics
Eiberg

Saber Frazier

Saber Yankauer

Orthopedics Opportunity
Key Procedure Targets

29

MIS Anterior Hip Arthroplasty

Shoulder Arthroplasty
Foot and Ankle
Hip Revisions
Trauma

Anterior Hip ArthroplastyVisualization of the Femoral Canal

30

30
30

Spine Opportunity
Key Procedure Targets

Posterior lumbar decompression

Posterior lumbar fusion
Anterior lumbar fusion
Anterior and posterior cervical
decompression
Anterior cervical fusion

31

31
31

Saber Frazier in Posterior Lumbar Fusion

32

Superior visualization. Ability to achieve rapid hemostasis.

32
32

Commercialization
Strategy
Expand deeper to new surgical
procedures and specialties
top/down strategy
~162,000 procedures
performed to date vs. ~92,000
as of Q1 2015
Expanding US sales organization
Customer account growth545
accounts Q1 2016 vs. 410 Q1
2015

33

Financial Overview

34

Topline Growth Year Over Year

35

Financial Summary
Results of Operations
(in thousands, except
percentages)

Three Months Ended

Mar. 31
2016

2015

Twelve Months Ended

Dec. 31
2015

2014

REVENUE

$6,404

$4,442

$21,031

$13,103

COST OF GOODS SOLD

$2,106

$1,722

$7,733

$4,630

Gross profit

$4,298

$2,720

$13,298

$8,473

67.1%

61.2%

63.2%

64.6%

$15,921

$10,833

$48,505

$28,225

($11,623)

($8,113)

($35,570)

($19,752)

Gross margin
OPERATING EXPENSES
LOSS FROM OPERATIONS

Cash on Hand as of 03/31/2016:

Additional Credit Facility

36

$33.9M
$7.5M

36
36

Investment Summary

Favorable Economics
Large Under-Penetrated Market
Significant Clinical & Product Advantages
with Strong IP
Experienced Management Team

37

38